FY2025 Earnings Forecast for CNTB Issued By Northland Capmk

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Research analysts at Northland Capmk decreased their FY2025 earnings estimates for shares of Connect Biopharma in a research report issued on Thursday, September 11th. Northland Capmk analyst C. Byrnes now anticipates that the company will earn ($0.92) per share for the year, down from their previous forecast of ($0.90). Northland Capmk has a “Strong-Buy” rating on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share.

Other analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Connect Biopharma in a research note on Wednesday, August 13th. Wall Street Zen raised Connect Biopharma to a “hold” rating in a report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Strong Buy” and a consensus target price of $7.00.

Connect Biopharma Trading Down 4.3%

Connect Biopharma stock opened at $1.56 on Monday. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.01. Connect Biopharma has a 12 month low of $0.51 and a 12 month high of $2.86. The stock’s 50 day moving average is $1.86 and its 200-day moving average is $1.18.

Hedge Funds Weigh In On Connect Biopharma

Several institutional investors have recently added to or reduced their stakes in CNTB. XTX Topco Ltd bought a new position in shares of Connect Biopharma during the 2nd quarter worth approximately $29,000. AlphaCore Capital LLC acquired a new position in shares of Connect Biopharma during the 2nd quarter valued at $78,000. Finally, Koa Wealth Management LLC acquired a new position in shares of Connect Biopharma during the 2nd quarter valued at $49,000. 58.72% of the stock is owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.